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Abstract
Background: Interleukin-15 is an immunostimulatory cytokine overexpressed in several autoimmune and inflammatory
diseases such as Rheumatoid Arthritis, psoriasis and ulcerative colitis; thus, inhibition of IL-15-induced signaling could be
clinically beneficial in these disorders. Our approach to neutralize IL-15 consisted in active immunization with structurally
modified human IL-15 (mhIL-15) with the aim to induce neutralizing antibodies against native IL-15. In the present study,
we characterized the antibody response in Macaca fascicularis, non-human primates that were immunized with a
vaccine candidate containing mhIL-15 in Aluminum hydroxide (Alum), Montanide and Incomplete Freund’s Adjuvant.
Results: Immunization with mhIL-15 elicited a specific antibodies response that neutralized native IL-15-dependent
biologic activity in a CTLL-2 cell proliferation assay. The highest neutralizing response was obtained in macaques
immunized with mhIL-15 adjuvanted in Alum. This response, which was shown to be transient, also inhibited the
activity of simian IL-15 and did not affect the human IL-2-induced proliferation of CTLL-2 cells. Also, in a pool of
synovial fluid cells from two Rheumatoid Arthritis patients, the immune sera slightly inhibited TNF-α secretion.
Finally, it was observed that this vaccine candidate neither affect animal behavior, clinical status, blood biochemistry
nor the percentage of IL-15-dependent cell populations, specifically CD56+ NK and CD8+ T cells.
Conclusion: Our results indicate that vaccination with mhIL-15 induced neutralizing antibodies to native IL-15 in
non-human primates. Based on this fact, we propose that this vaccine candidate could be potentially beneficial
for treatment of diseases where IL-15 overexpression is associated with their pathogenesis.
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Background
Cytokines are defined as short-range protein messengers
with important functions in the regulation of the immune
response and intercellular communications [1]. These
proteins have been shown to be overexpressed in the con-
text of several diseases, including allergies, autoimmune
disorders, cancer and some infectious diseases [2–5]. A
large number of therapeutic approaches aimed at inhi-
biting the activity of these molecules has been developed,
and there are over than 20 cytokine-targeting pharma-
ceutical agents currently approved for clinical use [6].
Interleukin (IL)-15, one of the members of this protein
family, is a pro-inflammatory cytokine that is overex-
pressed in several inflammatory disorders such as
Rheumatoid Arthritis (RA), psoriasis, ulcerative colitis
and sarcoidosis [7–11]. The participation of IL-15 in
the pathogenesis of autoimmune diseases has been
demonstrated by in vitro studies [12, 13], murine ani-
mal models [14] and clinical trials with an anti-human
IL-15 antibody (Ab), AMG714 [15]. In particular, IL-15
is an important player in the inflammatory processes
of RA, where it recruits circulating memory T cells in
the synovial membrane and may up regulate other
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pro-inflammatory cytokines through a variety of mecha-
nisms [16, 17]. Among these mechanisms are included the
induction of tumour necrosis factor alpha (TNF-α) pro-
duction through the activation of synovial T cells and mac-
rophages via a cell contact-dependent mechanism [18], as
well as the activation of Th17 lymphocytes driving up the
biosynthesis of IL-17 [19].
One possible approach for inhibiting the activity of
cytokines produced at pathogenic levels would be to
actively immunize patients with the relevant cytokine
coupled to a carrier protein or with the modified cyto-
kine [20, 21]. This strategy, aimed at inducing high titers
of neutralizing polyclonal auto-Abs against a pathogenic
cytokine in order to antagonize its harmful effects with-
out interfering with other physiologic processes [22, 23],
would possibly exhibit less adverse events than passive
immunization strategies, requiring much smaller num-
ber of doses, having a lower cost and not presenting the
potential problem of anti-Ab response [24, 25]. Exten-
sive overviews of anti-cytokines vaccination have been
published which based almost on the results obtained in
animal models, demonstrate that cytokine vaccination
may be an effective solution to the control of several
autoimmune diseases [26–31]. These data also suggest,
based on the absence of severe side effects, that active
anti-cytokine immunization represents a relatively safe
solution [32]. Taking into account these promising re-
sults, new clinical trials have been developed using
kinoids, which are approved by the Food and Drug
Administration for clinical human use [33].
The aim of the current research was to induce a neu-
tralizing Ab response against self-IL-15 as a potential
therapeutic strategy for diseases involving the overex-
pression of this cytokine. Although an anti-human IL-15
Ab, AMG714, has already been tested in clinical trials
[15], the cytokine itself has never been employed as a tar-
get for active vaccination. For our work, human IL-15 was
expressed in Escherichia coli following the procedure des-
cribed by Santos et al. [34]. The purified protein, denomi-
nated here as modified human IL-15 (mhIL-15), exhibits a
scrambled disulfide bonds pattern and it has an additional
Alanine residue at its N-terminus. In the present study,
non-human primates (NHP) Macaca fascicularis were
immunized with mhIL-15 adjuvanted in aluminum hy-
droxide (Alum), Montanide ISA-51 VG or Incomplete
Freund’s Adjuvant (IFA). The immune response of the
monkeys was analyzed by serum antigen-specific Ab
titers and the neutralizing capacity of the resulting sera
was determined in CTLL-2, an IL-15-dependent cell
line. The effect of these sera on the biological activity
of human IL-2 and simian IL-15 was also explored.
Additionally, we examined the effect of sera from ma-
caques immunized with Alum-adjuvanted mhIL-15 on
IL-15-mediated TNF-α production by synovial fluid
cells from patients with RA. Finally, the effect of
immunization with mhIL-15 on IL-15-dependent cell
populations was studied.
Methods
Animals. Handling and husbandry
Twelve adult macaques (Macaca fascicularis) of either
sex were used, weighting from 2 to 5 kg. All animals
were purchased from the National Center for Animal
Breeding (CENPALAB, Havana, Cuba) and maintained
in the animal facility of the Center for Genetic Engineering
and Biotechnology (CIGB, Havana, Cuba). An environ-
mental temperature of 22–29 °C and a light/dark cycle of
12:12 h were maintained throughout the study. The ani-
mals were housed individually in stainless steel cages
(90 × 60 × 60 cm) and randomized into groups of 3 to
receive mhIL-15 in each adjuvant. Three animals were
used as control (placebo group).
The monkeys were adapted to laboratory conditions for
at least 4 weeks. They were fed with fresh tomatoes,
guavas, bananas, and commercial chow (certificated granu-
lated formula CMQ 1600 ALYco; CENPALAB, Havana,
Cuba, containing 25 % of proteins, 3.5 % of crude fat and
3.8 % of crude fiber) twice a day with 150–300 g per
monkey according to their ages and body weights.
Water was provided ad libitum. The animals were anes-
thetized with an intramuscular injection of 10 mg/kg
ketamine hydrochloride (Liorad Laboratories, Havana,
Cuba) before immunization. Vital signs, temperature,
heart rate, blood pressure and body weight were registered
along the whole scheme before each immunization.
CTLL-2 cell line
CTLL-2 is a T cell-derived, IL-2 dependent cell line ob-
tained from C57bl/6 mice. These cells were grown in
RPMI medium 1640 (Thermo Fisher Scientific, USA)
containing 2 mM L-glutamine (Thermo Fisher Scientific,
USA), 50 μg/mL gentamicin (Sigma-Aldrich, USA), 10 %
heat-inactivated fetal bovine serum (FBS, Capricorn
Scientific, Germany) and 10 ng/ml recombinant human
IL-2 (R&D, USA). Cells were incubated at 37 °C with
5 % CO2, 95 % humidity. CTLL-2 cells were harvested
and used in log phase growth (Cell passage 5 after
thawing; Cell viability: ≥95 %). Prior to use, the cells
were washed 5 times with RPMI medium. The CTLL-2
cell bank was generated from cells directly obtained
from ATCC (TIB-214).
Purification of the recombinant mhIL-15
Expression of recombinant mhIL-15 in E. coli resulted in
the formation of insoluble inclusion bodies. After extrac-
tion in buffer containing 8 M urea (Merck, USA) in
phosphate-buffered saline (PBS, pH 7.4, Thermo Fisher
Scientific, USA), mhIL-15 was purified using size-exclusion
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chromatography (SEC) followed by reverse phase (RP) -
high performance liquid chromatography (HPLC). For
SEC, we used a HiLoad 26/600 Superdex 200 preparative
grade (60 cm × 26 mm, 34 μm, GE Healthcare, USA) col-
umn, which was operated at 4 mL/min. The mhIL-15-
containing fraction, detected at 226 nm, was then loaded
at 0.2 mL/min onto a C4 column (1 × 25 cm, 10 μm, Vydac,
USA). The proteins were separated using a mobile phase
containing 0.1 % trifluoroacetic acid (Sigma-Aldrich, USA)
and HPLC grade acetonitrile (Sigma-Aldrich, USA), with
0–80 % acetonitrile gradient over 70 min at 2.5 mL/min.
The separation was monitored at 226 nm [34].
Enzyme digestion of purified mhIL-15
Twenty micrograms of RP-HPLC purified mhIL-15
was suspended in 20 μL of 50 mM NH4HCO3 (Sigma-
Aldrich, USA) pH 8.0 and incubated for 4 h at 37 °C with
trypsin (Promega, USA) 1:100 (w/w) enzyme: mhIL-15 ra-
tio. Afterwards, endoproteinase Glu-C (Roche Biochemical
Reagents, USA) was added in tandem, in the same ratio
as trypsin, and incubated for 2 h at 37 °C. Peptides were
desalted by ZipTips (Millipore, USA), eluted in 3 μL of
60 % acetonitrile (Sigma-Aldrich, USA) in 1 % formic
acid (Caledon, Canada) and injected in a hybrid
quadrupole-time-of-flight (QTOF-2) mass spectrometer
(Micromass, UK).
Mass spectrometry
Intact protein samples as well as peptide digests were
analyzed by nano-electrospray ionization (ESI) - mass
spectrometry (MS) with a QTOF-2 mass spectrometer
(Micromass, UK). The samples were injected through
a slightly pressurized borosilicate capillary (Thermo
Scientific, USA). Capillary and cone voltages were set to
900 and 35 V, respectively. The mass range of 50–2000 Da
was calibrated with a mixture of sodium iodide and
cesium iodide (Sigma-Aldrich, USA). MS-MS was per-
formed by selecting a 2–3 Th mass window in the first
quadrupole and the precursors fragmented at collision
energies between 25 and 35 eV to achieve enough
structural information. Data acquisition and processing
were performed with the MassLynx version 3.5 package
(Micromass, UK).
Vaccine doses and schedule
All monkeys were screened for Abs against IL-15 pro-
teins, and considered naive with respect to the antigen
when specific Abs were undetectable by enzyme-linked
immunosorbent assay (ELISA, titer < 1:50; see methods
below). The animals were immunized subcutaneously at
several sites of the interscapular region with 200 μg of
mhIL-15 in a total volume of 0.5 mL adjuvanted with
either Alum (1.8 mg/mL, Brenntag Biosector, Denmark),
Montanide ISA-51 VG (50:50 v/v, SEPPIC, France) or
IFA (50:50 v/v, Sigma, USA). Three immunizations were
performed, spaced 1 month between the first and sec-
ond, and 2 months between the second and third. In the
case of the Alum-adjuvanted mhIL-15 group, there were
two additional immunizations at months 8 (fourth dose)
and 18 (fifth dose) after the third inoculation.
Blood samples were collected before beginning the
scheme (pre-immune), 15 days after each immunization,
and 3 and 6 months after the third dose. In the case of
animals immunized with Alum-adjuvanted mhIL-15,
samples were also taken 10 months after the fourth
dose. Complement was inactivated by incubating the
sera at 56 °C for 30 min and the sample were then
stored at -20 °C until used. Group serum pools were
used to evaluate the recognition of native or simian IL-15
by ELISA. For this purpose, equal volumes of serum from
animals of the same group were mixed.
ELISA for serum anti-IL-15 Abs
Specific Abs titers against IL-15 and the recognition of
native or simian IL-15 by immune sera were measured
through an ELISA as indicated below. EIA 96-well plates
(Costar, USA) were coated overnight at 25 °C with 1 μg/mL
of mhIL-15, simian IL-15 (previously obtained at the la-
boratory of CIGB, Havana, Cuba) or native IL-15 (R&D,
USA) in PBS pH 7.4. After 3 washes with 0.05 % Tween 20
(Calbiochem, Germany) in PBS, the plates were blocked
with 1 % bovine serum albumin (BSA, Sigma-Aldrich,
USA) in PBS for 1 h at 37 °C, followed by 3 washes.
PBS, 0.05 % Tween 20 and 0.01 % BSA-diluted sera or
pool of sera (starting dilution 1:1000 or fixed dilution
1:4000, respectively) were added to wells and incubated
for 2 h at 37 °C. Wells were then washed 3 times and
incubated with anti-monkey IgG (Fc specific)-peroxidase
Ab (Sigma, USA) diluted 1: 10 000 in PBS. After incu-
bating for 1 h at 37 °C, the plates were washed 5 times
and incubated with 100 μL of substrate solution (Ultra
3, 3′, 5, 5′-Tetramethylbenzidine Liquid Substrate Sys-
tem, Thermo Scientific, USA) for 15 min. The reaction
was stopped by adding 50 μL of 2 N sulphuric acid
solution (R&D Systems, USA) and the absorbance at
450 nm was measured with an ELISA plate reader (Biotrak
GE, Healthcare, USA). The 450 nm absorbance value cor-
responding to a PBS sample was subtracted from all the
obtained diluted serum readings. Ab titer was considered
as the highest serum dilution yielding at least twice the
value of the optical density (OD) at 450 nm of the pre-
immune serum from each animal. The data were processed
using the GraphPad Prism program v6.05 (GraphPad
Software, Inc.).
Effect of serum on the proliferation of CTLL-2 cells
To evaluate the neutralizing capacity of individual or
pooled samples, twofold serial dilutions of heat-inactivated
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sera (starting dilution 1:100 or 1:25 respectively) were per-
formed in 96-well plates (Costar, USA) in a volume of
30 μL of RPMI medium supplemented with 10 % FBS.
MAB247 and MAB202 (R&D, USA), which are com-
mercially available neutralizing anti-human IL-15 and
anti-human IL-2 Abs respectively, were used as positive
controls in a range of 1 μg/mL to 7.8 ng/mL (twofold
serial dilutions). Then, previously washed CTLL-2 cells
were added in amounts of 5 × 103 cells/well in 50 μL.
Afterwards, 300 pg/mL of native human IL-15 (R&D,
USA) or recombinant simian IL-15 or 50 ng/mL of hu-
man IL-2 (R&D, USA) in a volume of 20 μL was added
to each well, and the plate was incubated for 72 h at
5 % CO2 and 37 °C [35]. After 72 h, yellow tetrazolium
MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium
bromide, Sigma, USA) was added and the plates were fur-
ther incubated for 4 h [36]. Finally, 100 μL of a solution
containing 10 % sodium dodecyl sulfate (Merck, Germany),
0.1 N HCl (Sigma-Aldrich, USA) and 50 % isopropyl al-
cohol (Pharmco-AAPER, USA) were added per well.
Plates were read at 578 nm on a Multiscan (Sensident
Scan, Merck, Germany). Curve Expert Program V.1.3.80
(www.curveexpert.net/) was used to calculate the neutrali-
zing titers of sera from immunized monkeys with the anti-
IL-15 vaccine. These titers were expressed as the dilution
of sera that is required for inhibiting the proliferation by at
least 50 % (ID50). The data were graphed using the
GraphPad Prism program v6.05 (GraphPad Software, Inc.).
Inhibition of IL-15-mediated TNF-α production in synovial
fluid cells from patients with RA
After obtaining written informed consent, synovial fluid
from RA patients was extracted and incubated with
10 μg/ml hyaluronidase (Sigma, USA) for 45 min at 37 °C.
Synovial fluid cells were obtained after centrifugation at
1200 g for 10 min. The cells were incubated in 96-well
plates at 2 × 105 cells per well either with serum (dilution
1:1000), or 60 ng/ml of native IL-15 (R&D, USA), or a
combination of both. After 48 h of incubation, the su-
pernatants were collected and stored at -70 °C until fur-
ther evaluation. TNF-α concentration was determined
by ELISA (R&D Systems, USA) according to the manufac-
turer’s instructions. The data were graphed using the
GraphPad Prism program v6.05 (GraphPad Software, Inc.).
Determination of macaque CD8+ and CD56+ cell
populations from whole blood samples
One hundred microliters of blood containing 1 %
Ethylenediaminetetraacetic acid (EDTA-Na2, Sigma-
Aldrich, USA) as anticoagulant were gently homoge-
nized with 2 mL of lysis solution (0.15 M NH4Cl
(Sigma-Aldrich, USA), 1 mM KHCO3 (Sigma-Aldrich,
USA) and 0.1 mM EDTA in 0.2 L of distilled water),
keeping the samples in the dark for 15 min at 25 °C
and mixing them every 5 min. After this time, the re-
action was stopped by incubation on ice for 2 min, the
cells were centrifuged at 1200 g for 5 min and the
supernatant was discarded. The cell pellet was washed 3
times with 1 mL of cold PBS by gentle homogenization
and centrifugation at 1200 g for 5 min. Afterwards, the
cells were incubated on ice with 25 μL of Fluorescein iso-
thiocyanate (FITC)-labelled anti-human CD8 monoclonal
Ab clone 17D8 (Exalpha Biologicals, USA) diluted 1:3 and
an anti-human CD56 monoclonal Ab clone MEM-188
(BioVendor, Czech Republic) diluted 1:25 in PBS, keeping
the samples in the dark for 30 min. The cells were then
washed 3 times as indicated above and the samples labeled
with the anti-human CD56 Ab were incubated on ice for
30 min with anti-mouse IgG (whole molecule)-FITC Ab
(Sigma, USA) diluted 1:30 in PBS. After washing the
cells 3 times as described above, they were analyzed in
a PARTEC Pass II flow cytometer (Partec, Germany) by
collecting 20 000 events. The percentages of cells with
CD8 and CD56 surface markers were obtained from
the analysis of samples using FloMax software v2.4
(Partec, Germany).
Statistical analysis
The Shapiro-Wilk and Leveneʼs tests were used to verify
normality and homogeneity of variance. The comparison
of the levels of TNF-α and the percentages of CD8+ and
CD56+ cells was performed with Studentʼs T test for
paired samples. Statistical significance was set at p ≤ 0.05.
In all cases, the SPSS/PASW (Statistical Package for the
Social Sciences/ Predictive Analytics Software) Statistics
for Windows version 18 (Chicago: SPSS Inc.) was used.
Results
Characterization of mhIL-15 by MS
The purification process described for the recombinant
human IL-15 expressed in E. coli allowed a 95 % of protein
purity [34]. This protein contains two disulfide bridges in
its structure. Figure 1 depicts the spectrum of multiple
charge ions of intact IL-15 obtained by ESI-MS, where a
single species of protein outstands with a molecular mass
of 12 840.45 ± 0.13 Da. This molecular mass is similar to
the expected molecular mass of 12 840.59 Da obtained
from the cloned DNA sequence corresponding to the
presence of two disulfide bonds and an additional alanine
residue in the N-terminal of protein.
Amino acid sequence of IL-15 was verified by ESI-MS
peptide-analysis of trypsin and Glu-C tandem enzyme
digestions. Table 1 shows the experimental molecular
mass and the sequence assignments.
Sequencing of peptides m/z 441.64 and 747.34
(double charged) confirmed that the purified IL-15 con-
tains disulfide bonds between Cys36- Cys43 and Cys86-
Cys89 (Fig. 2a and b). This disulfide arrangement is
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different to the one described by Pettit for the native pro-
tein Cys35-Cys85 and Cys42 -Cys88 [37]. These results
confirmed that the major fraction of the human IL-15 pre-
viously described by our group [34] was structurally modi-
fied with respect to the native protein.
Abs response in NHP immunized with mhIL-15 using
three different adjuvants
Figure 3a depicts the anti-IL-15 Abs titers detected by
ELISA in serum from macaques immunized with mhIL-15
in Alum, Montanide or IFA after the third immunization.
Average titer was higher than 1:20000 in all groups, except
in the pre-immune and placebo monkeys. The highest
response was obtained in the group immunized with
IFA eliciting an average titer of 1:28351; while in the
Alum and Montanide groups the calculated average
titer was 1:24660 and 1:24616, respectively.
Recognition of native IL-15 with the correct disulfide
bridges was assessed by ELISA, but due to the few
amount of available cytokine, we evaluated the pool of
sera from each group. As shown in Fig. 3b, OD 450 nm
values in immunized groups were, at least, four times
higher than the one obtained for the placebo group. This
result demonstrates that anti-IL-15 Abs generated by
immunization with mhIL-15 recognized native IL-15
immobilized on the plate.
Also, neutralizing activity of sera from macaques im-
munized with mhIL-15 was evaluated by a CTLL-2 cell
proliferation assay in presence of native human IL-15
[35]. We observed a neutralizing effect of sera corres-
ponding to the third immunization in CTLL-2 cells.
Fig. 1 Mass spectrum of the intact IL-15 purified from E. coli. Signals corresponding to multi-charged ions are showed for the molecule
(B8, B9, B10, B11, B12 and B13) and the myoglobin (A9, A10, A11, A13, A14, A15, A17, A18 and A19) used as an internal standard (Theoretical molecular
mass 16951.50 Da)
Table 1 Peptides generated by IL-15 digestion with trypsin/Glu-C enzymes observed by ESI-MS
Experimental m/z Theoretical m/z Charge Error Localization and amino acid sequence
565.73 565.75 1 0.02 55SGDASIHDTVE65
629.81 629.84 2 0.03 1ANWVNVISDLK11
747.32 747.34 2 0.02 43CFLLE47 30SDVHPSC36K37
801.43 801.47 2 0.04 48LQVISLE54
441.64 441.64 2 0.00 84SGC86KEC89EE91
936.95 936.99 2 0.04 66NLIILANNSLSSNGNVTE83
955.95 956.00 2 0.05 100FLQSFVHIVQMFINTS115
1060.49 1060.52 2 0.03 12KIEDLIQSMHIDATLYTE29
Cys43-Cys36 and Cys86-Cys89 are linked by disulfide bonds
m/z mass-to-charge ratio
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Figure 3c shows neutralizing titers for animals immu-
nized with mhIL-15 using three different adjuvants. The
higher neutralizing capacity was obtained in the group
using Alum as adjuvant with titers of 1:1690, 1: 3790
and 1:2135, whereas sera from the Montanide group
showed values of 1:897, 1:1987 and 1:1275. Sera from
the group immunized with IFA showed higher neutralizing
effect than the Montanide group with values of 1:800;
1:3200 and 1:2400. This result indicated that anti-IL-15
Abs produced by immunization with mhIL-15 inhibits na-
tive IL-15 biological activity in a cell line that proliferates
in response to IL-15. Based on these results and some
elements mentioned in the discussion section we chose
Aluminum hydroxide as the adjuvant for vaccination
with mhIL-15.
Abs response in macaques immunized with mhIL-15 in
Alum throughout the whole scheme
Spaced immunizations were performed using Alum as
adjuvant to address the duration of the Abs response.
Figure 4a summarizes the course of the Abs response to
the mhIL-15/Alum group throughout the scheme. Three
months after the third immunization, the anti-human
IL-15 Abs titers declined in more than 50 % with an
average titer of 1:9475 while after the six months the
average titer was 1:3930. In order to assess if we could
reach levels of Abs titers similar to those obtained pre-
viously through re-immunization, we performed two
additional immunizations. As shown in the graph, the
Abs titers after the fourth immunization were very similar
to those achieved after the third inoculation. Decreases in
specific Abs titers were detected in the samples taken
300 days after the fourth dose (average titer 1:1333). How-
ever, in response to the fifth immunization we observed a
full recovery of the Abs response, to levels similar to those
obtained in previous immunizations (Fig. 4a).
Effects of sera from immunized macaques were evalu-
ated using the CTLL-2 cell proliferation assay aiming to
assess whether the titers of anti-IL-15 Abs obtained by
ELISA corresponded with a neutralizing Abs response.
Figure 4b depicts effects on the proliferation of the
CTLL-2 cells of serum obtained from a macaque immu-
nized with mhIL-15 in Alum. In correspondence with
the results obtained by ELISA, highest neutralizing effects
were present in sera of monkeys corresponding to 15 days
after third, fourth and fifth immunizations. Neutralizing
effects were smaller due to decreased titers of anti-IL-15
Abs as observed in a serum sample at 6 months after the
third immunization. In agreement with the absence of
Abs titers, pre-immune serum did not affect cell prolifera-
tion; however, commercial anti-human IL-15 neutralizing
Abs inhibited proliferation in a dose-dependent manner.
Similar results were obtained when the sera of other
animals from the same group were assessed.
Effect of the immune sera on the recognition and the
activity of simian IL-15
In order to evaluate the recognition of sera from immu-
nized animals on self-IL-15 and their effect on the ac-
tivity of simian IL-15, we obtained this cytokine by
cloning its cDNA upon RNA isolated from PBMC of
Macaca fascicularis in E. coli (unpublished results).
Fig. 2 Fragment mass spectra of disulfide bonds containing peptides of mhIL-15 after tandem trypsin/Glu-C digestion. The disulfide bonds between
cysteine 36–43: 43CFLLE47 30SDVHPSC36K37 (a) and cysteine 86–89: 84SGC86KEC89EE91 (b) were shown
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First, recognition of simian IL-15 by Abs from sera of
the Alum group was assessed by ELISA. As illustrated
in Fig. 5a, the sera recognized simian IL-15 immobilized
on the plate. The OD 450 nm values corresponding to the
immunized groups were, at least, 5 times higher than that
obtained from the placebo group. In addition, these sera
inhibited the activity of simian IL-15 and showed a neu-
tralizing effect in a dose-dependent manner (Fig. 5b). The
calculated ID50 values were similar among the three
animals (1:831, 1:635 and 1:636).
Effect of the immune sera on IL-2 proliferative activity in
CTLL-2 cells
To study the specificity of the neutralizing activity of
sera obtained from the Alum group, we assessed their
effects on human IL-2-induced proliferation of CTLL-2
cells. As observed in Fig. 6, the Abs generated after
mhIL-15-based immunization had no effect on human
IL-2-induced proliferation of CTLL-2 cells; while the
commercial neutralizing anti-human IL-2 Ab exhibited a
dose-dependent inhibition.
Effect of serum on TNF-α secretion in synovial cells from
RA patients
In order to assess activity of sera from immunized mon-
keys on other IL-15-induced biological functions, we
measured effects on TNF-α secretion of one serum from
Alum group corresponding to 15 days after the third
immunization. For this purpose, we determined levels of
IL-15 in synovial fluids from patients with RA [38] and
we selected 2 patients with high concentration of this
cytokine (≥25 pg/mL). In this experiment, we found that
Fig. 3 Abs response in macaques immunized with mhIL-15 corresponding to 15 days after the third immunization. a ELISA for Abs titers against
IL-15. The plate was coated with 1 μg/ml mhIL-15 and the serum from each animal was evaluated in twofold serial dilutions (starting dilution 1:1000).
All animals developed an Abs response, except pre-immune and placebo macaques. The line represents the mean values of Abs titers calculated from
duplicate samples of individual monkeys (n = 3) corresponding to each experimental group. b ELISA for recognition of native IL-15 by Abs from sera of
immunized macaques. The plate was coated with 1 μg/ml native human IL-15 and the pool of sera from each group was evaluated in fixed dilution,
1:4000. c Serum neutralization titers of macaques calculated from the data obtained in the CTLL-2 cell proliferation assay. The line represents
the mean values of neutralization titers (expressed as 1/ID50) calculated from duplicate samples of individual animals (n = 3). The ID50 was
determined by inhibiting of human IL-15-induced proliferation of CTLL-2 cells
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serum from an animal immunized with mhIL-15 in Alum
inhibited TNF-α secretion induced by exogenous IL-15 in
synovial cells. Additionally, this serum diminished signifi-
cantly (p 0.05) the baseline levels of TNF-α secreted by
these cells (Fig. 7).
Effect of the vaccine on IL-15-dependent cell populations
Percentages of CD56+ and CD8+ cells before and after
the fifth immunization were determined in order to
study the effect of vaccination on IL-15-dependent cell
populations, such as CD56+ NK and CD8+ T cells. These
samples showed low and high titers of anti-IL-15 Abs,
respectively.
Table 2 shows the quantitation of CD56+ and CD8+ cells
determined by flow cytometry in samples from animals im-
munized with mhIL-15 in Alum. In this case, the samples
did not exhibited statistically significant differences in per-
centages of IL-15-dependent cells with CD56 (p 0.658) and
CD8 (p 0.684) markers.
Clinical, behavioral, and laboratory parameters
During the observational time of 540 days, no differences
were observed in immunized animals with respect to
initial clinical observations, which included body weight,
rectal temperature, and respiratory and cardiac rates. No
lesions appeared at the inoculation site in immunized
animals except for animals immunized with IFA. Addi-
tionally, no changes in any tested hematologic or blood
biochemical parameters were observed.
Discussion
In the current work, we evaluated a therapeutic vaccine
composed of recombinant mhIL-15 as antigen. Our goal
was to generate neutralizing antibodies which could in-
hibit IL-15 pathological effects. This vaccine could be
used for treatment of autoimmune diseases, leukemia or
transplant rejection, scenarios where uncontrolled ex-
pression of IL-15 is related to disease’s course [39–41].
At first, the structurally modified recombinant protein
was expressed in the host E. coli. Recombinant mhIL-15
obtained by our group contains disulfide bridges between
contiguous cysteines C36-C43 and C86-C89, unlike previous
reported cysteines C35-C85 and C42-C88 for native IL-15
[37]. However, it is noteworthy that IL-15 obtained by
us has an Alanine residue at the N-terminus of the pro-
tein before the initial codon. Consequently, location of
Fig. 4 Abs response in macaques from the Alum group throughout the immunization scheme. a Titers of anti-IL-15 Abs detected by ELISA in
macaques immunized with mhIL-15 adjuvanted in Alum. The plate was coated with 1 μg/ml mhIL-15 and serum was evaluated in twofold serial
dilutions (starting dilution 1:1000). The Abs titers of pre-immune animals, placebo group and the monkeys immunized with mhIL-15 in Alum after
the second, third, fourth and fifth immunization are shown. The line represents the mean values of Abs titers calculated from duplicate samples
of individual animals (n = 3) during the scheme. b Proliferation assay in CTLL-2 cells with the serum of one animal from the Alum group. Cells were
cultured in the presence of native IL-15, IL-15 plus dilutions of the pre-immune serum, or serum from each immunization (starting dilution 1:100), IL-15
plus serial dilutions of an anti-human IL-15 Ab and cells culture in medium without cytokine. Cell proliferation was evaluated by MTT staining. Similar
results were obtained when the sera of other animals from the same group were assessed. d: days after immunization; m: months after immunization
Rodríguez-Álvarez et al. BMC Immunology  (2016) 17:30 Page 8 of 14
cysteines in the mhIL-15 sequence is displaced in one
residue compared with native IL-15 [37]. This struc-
tural modification is privileged due to the reducing en-
vironment in the cytoplasm of the bacterium, which
does not favor formation of disulfide bonds. Additionally,
we speculate that this modification can favor exposure of
subdominant or cryptic epitopes that promote an effective
Ab response against the native protein.
Selection of a suitable animal model is important for
assessing immunogenicity of a recombinant protein. The
NHP were selected because they are the specie of the
greatest homology with humans in the amino acid
sequence of IL-15, reporting a 97 % similarity between
proteins of both species [42]. The latter is suitable for
testing the concept that through vaccination with mhIL-15,
a rupture of the immune tolerance can be achieved. Also,
there is a high similarity between simian and human IL-15
regarding biological activity and recognition of receptor
subunits [43] which could be advantageous to our ap-
proach. Thus, to assess the immunogenicity of IL-15
vaccine in NHP, we used three distinct adjuvants: Alum,
Montanide and IFA. Immunization with mhIL-15 gener-
ates a response of anti-IL-15 Abs with titers superior to 1:
20000 after the third immunization in all groups. These
Fig. 5 Recognition and neutralizing capacity of sera from the Alum group in presence of simian IL-15. a ELISA for recognition of simian IL-15 by
Abs from sera of immunized macaques. The plate was coated with 1 μg/ml recombinant simian IL-15 and it was incubated with the pool of sera
per group diluted 1:4000. b Inhibition of simian IL-15-induced proliferation of CTLL-2 cells by sera from the Alum group. Cells were cultured in
the presence of simian IL-15, simian IL-15 plus serial dilutions of serum (starting dilution 1:25) or medium. Cell proliferation was evaluated by MTT
staining. All tested sera correspond to 15 days after the third immunization
Fig. 6 Effect of sera from Alum group on IL-2-dependent proliferative activity in CTLL-2 cells. Cells were cultured in presence of IL-2, IL-2 plus
serial dilutions of sera (starting dilution 1:25), IL-2 plus serial dilutions of an anti-human IL-2 Ab or medium. Cell proliferation was evaluated by
MTT staining. All tested sera correspond to 15 days after the third immunization
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results indicate a rupture of B cells tolerance as conse-
quence of immunization and generation of specific Abs
against the cytokine. Higher Abs titers were obtained in
the group immunized with IFA, in correspondence with a
potent immunostimulatory effect described for this adju-
vant [44], although it also caused toxicity in every animal
of this group, presenting septic ulcers at the site of inocu-
lation. We are aware that this toxicity hinders its use in
humans; nevertheless, we incorporated it in our scheme as
an experimental control based on previous results not
shown in this work.
On the other hand, Alum is the most widely used ad-
juvants in human vaccines [45], and its use elicits strong
humoral immune responses primarily mediated by
secreted antigen-specific Abs [46]. This constitutes a
favorable element, considering that the aim of active
immunotherapy against cytokine is to obtain blocking
Abs from the immune system of the treated patient. In
addition, Alum is a poor inducer of cell-mediated im-
mune responses and is unsuitable for vaccines that re-
quire a strong cellular immune response [47]. Considering
this elements and the fact that its use generated the re-
sponse of anti-IL-15 Abs with higher neutralizing capacity,
we selected Alum as adjuvant for active immunization
with mhIL-15. However, taking into account the number
of animals used in this study, it would be necessary to use
additional animals per group to confirm the superiority of
alum over other adjuvants like Montanide.
Due to the proliferation within some inflamed tissues,
it is mandatory to avoid accumulation of T cells in most
of the diseases where cytokines are chronically secreted.
Therefore, it is critical when designing vaccines against
cytokines to disrupt B-cell but not T-cell tolerance to
self-cytokines, thereby eliciting production of neutrali-
zing Abs in high titers [1, 23]. In this work, we showed
that immunization with mhIL-15 generated neutralizing
Abs against native IL-15. However, it is still necessary to
demonstrate that immunization with this cytokine does
not elicit a specific cellular response.
Our results indicated that Abs response was self-
regulated when Alum was used as adjuvant. In our scheme,
Abs titers begin to decrease after three months post-
immunization, which could be due to limited produc-
tion of these Abs by the activated B cells in absence of
specific T helper cells [48]. Noteworthy, before a new
re-immunization, the Abs response recovered to a simi-
lar extent of that achieved in previous immunizations.
These results suggest the generation of B memory cells,
which are activated in response to a new immunization,
so that it does not generate a response with sustained
production of Abs, but rather a controlled response by
immunization. Application of this vaccine would allow
manipulation of treatments in such a way that may in-
duce a controlled and not sustained Abs response
against IL-15 in diseases such as RA which are charac-
terized by periods of crisis and remissions [49]. Particu-
larly, the frequency of boosters could be optimized in
this disease monitoring both Abs titers by ELISA and
neutralizing activity in immune sera.
Another important result was recognition and neu-
tralization of native IL-15 by Abs generated by im-
munization. This element is favorable if one considers
Fig. 7 Effect of serum on TNF-α production mediated by IL-15 in synovial cells from RA patients. Synovial fluid cells were incubated with serum
(fixed dilution 1:1000), or with 60 ng/ml of IL-15, or a combination of both. After incubation, supernatants were collected and levels of human
TNF-α were quantified by ELISA. The tested serum corresponds to one animal from the Alum group and was taken 15 days after the third immunization
Table 2 Percentages of CD56+ and CD8+ cells from whole blood of monkeys
CD56+ cells (%) CD8+ cells (%)
Animals Before the fifth immunization After the fifth immunization Before the fifth immunization After the fifth immunization
mhIL-15/Alum1 13.8 13.9 20.2 16.0
mhIL-15/Alum2 5.9 6.7 31.3 37.2
mhIL-15/Alum3 5.9 3.5 17.9 20.4
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that our aim with an anti-IL-15 vaccine is to develop a
specific Abs response against native IL-15 capable of
neutralizing this cytokine overexpression and its patho-
logical effect. A native IL-15 containing disulfide bonds
in correct positions was used in all test. Our results in-
dicate that Abs present in immune sera from macaques
neutralized native IL-15 activity; showing correspondence
between Abs titers and neutralizing effects.
Although our strategy did not include the introduction
of foreign immunodominant T-helper epitopes into na-
tive structure of the cytokine nor the fusion of the self-
protein to a carrier, we demonstrated that immunization
with mhIL-15 generated a specific neutralizing Abs re-
sponse against native IL-15. We speculate that structural
modifications of the mhIL-15 could favor an exposure of
dominant epitopes that cooperates with B cells in gener-
ating a specific Abs response against IL-15. In previous
studies, our group found that at least fusion of mhIL-15
with P64K protein as a carrier generates an antibody res-
ponse that does not neutralize native IL-15 (unpublished
results), but we do not rule out the possibility that fusion
to another protein such as Keyhole limpet hemocyanin
(KLH), Virus-like particles (VLP) or Ovalbumin (OVA)
could develop a neutralizing Abs response against IL-15.
On the other hand, the specificity of neutralizing sera
was determined in presence of IL-2, considering that
CTLL-2 cells also proliferate with this cytokine. Although
receptors for IL-2 and IL-15 share the β and γc subunits
and some biological functions due to redundant effect
have been described for these proteins [50], in this study
we demonstrate that sera generated by immunization with
mhIL-15 does not inhibit IL-2-induced proliferation. In
this cell line, no toxic effect caused by sera on CTLL-2
cells was observed, supporting the statement that the de-
crease on cell proliferation obtained in previous experi-
ments with native IL-15, was due to the neutralizing
capacity of Abs generated by immunization.
It has been proposed that an IL-15 antagonist could
be useful for treating some autoimmune diseases in
which IL-15 acts as proinflammatory cytokine. Particu-
larly, high levels of IL-15 have been found in synovial
fluids from RA patients [51], and it is known that in re-
sponse to IL-15, synovial T cells secrete TNF-α directly
and induce TNF-α synthesis by macrophages through
cognate interactions [18, 52]. In this work, we demon-
strated that immunization with mhIL-15 in Alum gen-
erates a neutralizing serum that slightly diminished
levels of TNF-α in synovial cells, with or without IL-15
stimulation. Although, the number of tested patients is
very small, these results suggest that this vaccine could
be useful for treating RA taking into account that TNF-
α is an important and validated target in RA, neverthe-
less additional experiments will be necessary to confirm
this hypothesis.
Despite a high homology between human and simian
IL-15 (97 % amino acid sequence identity), our results
demonstrated that sera from animals immunized with
mhIL-15 inhibited simian IL-15 biological activity in a
CTLL-2 cell proliferation assay. This finding suggests
that Abs against epitopes present in simian IL-15 were
generated through vaccination, validating the use of this
species as a model in evaluating the proposed strategy.
In this sense, as security elements, we assessed the effects
of immunization on cell populations that are important
targets of IL-15, such as CD56+ NK and CD8+ T cells
[53, 54]. We found that vaccination with a mhIL-15
adjuvanted in Alum did not affect the percentage of
cells with CD8 and CD56 markers.
Although in human two phenotypically and function-
ally distinct peripheral blood NK cell subsets have been
described based on the expression of CD56 and CD16
[55], in NHP the ability to investigate the role of NK
cells in the models of disease has been greatly limited by
the lack of appropriate phenotypic markers for this cellu-
lar population. In this study we used CD56 as a marker to
assess NK cell. However, in previous studies in primates,
the expression of CD56 was defined as a marker of a
minor subset of NK cells [56–59]. To confirm that vaccin-
ation do not affects the number of entire NK cells, it
would be necessary further experiments before carry out a
clinical trial with this approach. For this purpose we could
use the human NK receptor monoclonal Abs for NKp80
and NKG2A, alone or in combination with anti-CD16
monoclonal Ab to identify the entire NK cell population
in NHP. While anti-NKp80 recognized virtually all NK
cells in macaques, anti-NKG2A proved to be significantly
more specific than anti-NKp80 for simian NK cells.
Nevertheless, the same specific recognition of NK cells
could be achieved with anti-NKp80 if used in combination
with anti-CD16 [60].
This aspect is important in assessing the safety of the
strategy we propose. While the goal is to apply this vac-
cine for therapeutic purposes in patients with elevated
levels of IL-15, it is important to study a possible effect
of immunization on the physiological activity of this
cytokine in individual’s immune defense. Despite the fact
that high affinity Abs against cytokines will not impair the
physiology of normal tissues [47] and that anti-cytokine
vaccination have been demonstrated to be safe in experi-
mental and clinical studies [61–63], it would be necessary
to demonstrate that immunization with IL-15 does not
interfere with functionality of these cell populations.
In our research was not possible to study the variation on
IL-15 levels in serum from immunized macaques because
in physiological conditions exists many regulatory elements
that allow the modest expression of IL-15 [64]. In fact, in
serum from healthy controls as well as in healthy NHP, the
median IL-15 value was less than 2 pg/mL [65, 66], so it is
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difficult to detect changes at this level. Therefore, it is tricky
to study the variation on IL-15 levels in serum from the
NHP used in the current work, although we agree that this
is informative data and will be considered in the clinical
trials of this therapeutic vaccine.
In parallel, all animals were monitored during the
scheme by measuring temperature, body weight, heart
rate and behavioral state. The biochemical parameters in
blood were into the physiological limits established for
these species. Only severe local lesions are observed in
inoculation sites of animals immunized with IFA, some
adverse events associated with use of this adjuvant [67].
As future purposes of this work, it is necessary to demon-
strate effectiveness of this vaccine in an animal model of
the disease and in humans through clinical trials. Never-
theless, the use of NHP as a model can guide us on the
clinical potential of this cytokine in humans due to the
high homology between these species.
Conclusion
This study shows that the immunization with mhIL-15
using three different adjuvants: Alum, Montanide and
IFA is able to generate specific neutralizing Abs against
self-IL-15 in NHP. Interestingly, the highest neutralizing
response was obtained in macaques immunized with
mhIL-15 adjuvanted in Alum, although, it is necessary
to confirm the superiority of this adjuvant over others
with additional animals. The anti-IL-15 Abs elicited by the
immunization were capable to recognize and neutralize
the activity of native and simian IL-15. Additionally, the
immunization did not affect the percentage of CD56+ NK
and CD8+ T cells, nor the clinical signs or blood bio-
chemical parameters of the monkeys. Furthermore, in
cells from synovial fluid of two patients with RA, the
anti-IL-15 Ab slightly inhibited the expression levels of
TNF-α. In summary, the results presented in this paper
demonstrate for the first time the immunogenicity and
some safety aspects of a vaccine based on active im-
munization with mhIL-15 in healthy NHP. This strategy
could be useful in the treatment of patients with disorders
in which overexpression of IL-15 has been related with
the course of the disease.
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